Ultragenyx Pharmaceutical Inc. (RARE) · Nov 3, 2026 · Restructuring

Ultragenyx earnings miss as 20% layoffs target 2027 profit

20% workforce reduction — RIF expanded from prior 10% plan to approximately 20% of employees

Ultragenyx’s Q3 earnings missed revenue expectations, while a larger restructuring and $413M PRV sale support its 2027 profitability target.

Ultragenyx is moving from late-stage biotech development into commercial execution after securing approvals for GENGLYCOS and FAYUVI, but it is doing so with a smaller pipeline and a much tighter cost base. Earlier in 2026, management had already announced a roughly 10% workforce reduction and a path to 2027 profitability; the new filing substantially deepens that reset.

The quarter missed the revenue bar even as the loss improved. Third-quarter revenue was $173 million versus a published consensus of about $182 million, while the $1.16 per-share loss was better than the roughly $1.10 expected loss only in the sense that the reported loss was larger; on a conventional EPS comparison, -$1.16 is worse than -$1.10. Revenue grew 8% year over year, but the quarter did not show the commercial acceleration investors were looking for from the newly approved gene-therapy products.

Figure	Q3 2026	Q3 2025	Consensus / prior guide
Total revenue (Selected Financial Data)	$173M (+8.1%)	$160M	~$182M
Net loss per share (Net Loss)	$(1.16)	$(1.81)	~$(1.10)
R&D expense (Statement of Operations)	$154M (-28.7%)	$216M
SG&A expense (Statement of Operations)	$97M (+11.5%)	$87M
2026 total-revenue guide (Revenue Guidance)	$730M–$760M		$730M–$760M

The bigger message is a forced acceleration of the profitability plan. Ultragenyx is cutting approximately 20% of employees, winding down GTX-102, terminating UX701 after it failed to meet its advancement criteria, and targeting 2027 R&D below $350 million and SG&A below $375 million. 〔0〕 This is financially supportive of the 2027 profitability target, but it also shows that management now needs a materially smaller organization and narrower development portfolio to reach it.

The cash picture improves, but the underlying operating position remains demanding. The completed GENGLYCOS PRV sale brought in $210 million gross, with 20% payable to the NIH, and the pending FAYUVI PRV sale would take aggregate PRV proceeds to $413 million and expected net proceeds to about $350 million. That capital is meaningful against $401 million of cash, cash equivalents and marketable securities at September 30, but it is nonrecurring and does not solve the need to execute the new launches.

The pipeline is being concentrated around fewer, more important shots on goal. The company is redirecting R&D toward DTX301 data expected in the first half of 2027, a possible regulatory path for UX143, and early programs while abandoning UX701. 〔1〕 That improves focus and reduces spending, but it raises the importance of successful launches and the next clinical milestones.

Bottom line: This is not a clean earnings beat: revenue fell short of expectations, and the sharper restructuring exposes more strain than the company’s upbeat framing suggests. The filing does strengthen the funding and cost-control case for 2027 profitability, but mainly by narrowing the business and raising execution dependence on the two new gene-therapy launches.

What to watch next

DTX301 Phase 3 data expected in the first half of 2027

Original filing on SEC EDGAR

More Ultragenyx Pharmaceutical Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Ultragenyx earnings miss as 20% layoffs target 2027 profit

What to watch next

More Ultragenyx Pharmaceutical Inc. news

Breaking down Wall Street's information edge.